Egypt’s Hassan Allam Holding has said one of its subsidiaries has signed a memorandum of understanding with Abu Dhabi-listed Modon Holding to supply construction materials for the Ras El Hekma ...

Vividion Therapeutics has dosed the first subject in a Phase I trial of an oral inhibitor, VVD-159642, aimed at treating ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations ...

We achieved activation of pathways downstream of Ras by infecting tv-a + cells with an RCAS vector encoding the G12D mutant form of K-Ras (RCAS-Kras). Pathways downstream of Akt were activated by ...

"These are the so-called RAS inhibitors." Research indicates that RAS inhibitors target a specific protein that signals the body to behave in a way that can halt cancer growth. "K-RAS is a gene ...

“There is so much excitement around these RAS therapies,” says Shaw, a lung cancer specialist who returned to Dana-Farber in 2024 after 5 years at Novartis. Shaw and Andrew Aguirre, an ...